Medicus Pharma Ltd.
MDCXHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Medicus Pharma Ltd. focuses on Drug Manufacturers - General services and products. Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. Valued at $10.9M, MDCX is a micro-cap name in its sector. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Market Cap
$10.9M
Beta
-0.48
P/E (TTM)
—
P/E (Fwd)
-0.36
EPS (TTM)
$-2.36
EPS (Fwd)
$-0.48
ROE
-7446.1%
ROA
-110.7%
Cash
$15.2M
Total Debt
$21.6M
Free CF
-$16.2M
52W Change
-91.8%
Annual Financials
Cash vs Debt
Where MDCX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MDCX finished 48.00% below its 150-day moving average ($0.50) and 67.50% below its 200-day moving average ($0.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDCX overbought or oversold?
At the September 3, 2026 close, MDCX's RSI(14) was 22.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $15.2M in cash, though total debt stands at $21.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$16.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -7446.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Medicus Pharma Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Medicus Pharma Ltd.'s trajectory.